|
|
|
|
| Top Story |
 |
|
Pharm Exec's 2017 Pipeline Report |
The industry is readying for a leap into a new age of complex therapies. Elaborate manufacturing and soaring drug costs, however, loom as deep chasms to cross in bridging the potential with reality. By Casey McDonald
… /Read more/ |
|
|
| Advertisement |
ZS research: Three reasons why TV DTC advertising is up and advice for DTC budget decisions.
 Read this article
|
|
| From the Editor |
 |
|
The Pipeline: Pressures from Beyond |
The influx of treatment breakthroughs and expanding science has not silenced the debate over the productivity of biopharma's R&D model, and the looming challenges for R&D decision-makers
… /Read more/ |
|
|
| Advertisement |
Podcast: Assuring Trust in the Digital Space
Pharm Exec talks to Mollie Shields-Uehling, a leading advocate for high-assurance identity trust for cyber-transactions in the biopharmaceutical industry. Listen to the podcast for a timely, 15-minute discussion covering topics like cyber/technical security; eHealth regulatory compliance; work flow automation, the benefits of eSignature programs, and collaboration around key aspects of drug development like the administration of clinical trials and research partnering.
 Click here to listen >>
|
|
|
|
| Advertisement |
How the Life Sciences Cloud Coalition Is Driving Greater Innovation and Collaboration for Sponsors
On Demand
 Learn more
|
|
| Advertisement |
Achieving Success in the Biosimilar Market
On Demand
 Learn more
|
|
|
ADVERTISEMENT
|
| Advertisement |
Supporting internal and external decision-making through effective MSL activities
On Demand
 Learn more
|
|
| Industry update |
| //Protea Biosciences Group (Morgantown, WV) appointed David Halverson as President.//Orthobond Corporation (North Brunswick, NJ) announced that Charles S. Ryan, JD, PhD, is joining the company as Chief Executive Officer and a member of the Board of Directors.//AVROBIO (Cambridge, MA) announced three key hires. Nerissa Kreher joind as Chief Medical Officer for Rare Diseases, Kathryn McNaughton joined as Senior Vice President of Portfolio and Program Management and Richard Pfeifer joined as Director of Preclinical Development.// |
|
|
